-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Gastric Cancer Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Metastatic Melanoma Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Solid Tumor Drug Details: IMM-6-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Metastatic Pancreatic Cancer Drug Details: IMM-6-415 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Non-Small Cell Lung Cancer Drug Details: IMM-6-415...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-6-415 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-6-415 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-6-415 in Metastatic Colorectal Cancer Drug Details: IMM-6-415 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-1-104 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-1-104 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Pancreatic Ductal Adenocarcinoma Drug Details: IMM-1-104 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-1-104 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-1-104 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: IMM-1-104...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-1-104 in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-1-104 in Lung Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-1-104 in Lung Adenocarcinoma Drug Details: IMM-1-104 is under development for...
-
Product Insights
NewBiofourmis Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biofourmis Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biofourmis Inc (Biofourmis) is a provider of advanced technology and clinical support for home care and digital therapies. The company offers Care@Home platform to deliver virtual care for patients with acute, post-acute, and chronic medical conditions; and software-based therapeutics to treat and manage patients with unmet clinical needs. Its DCT (decentralized clinical trials) solution provides telehealth, active ePRO and passive...